Sigma-2 Receptor Agonists as Possible Antitumor Agents in Resistant Tumors: Hints for Collateral Sensitivity
作者:Mauro Niso、Carmen Abate、Marialessandra Contino、Savina Ferorelli、Amalia Azzariti、Roberto Perrone、Nicola Antonio Colabufo、Francesco Berardi
DOI:10.1002/cmdc.201300291
日期:2013.12
adenocarcinoma cells, with similar activity in the corresponding doxorubicin‐resistant MCF7adr cell line. Surprisingly, a few compounds, including 25, displayed enhanced activity in MCF7adr cells over parent cells, recalling the phenomenon of collateral sensitivity, which is under study for the treatment of drug‐resistant tumors. All of the compounds showed interaction with P‐glycoprotein (P‐gp), and 15
与促进新的抗肿瘤剂的开发为目标,高亲和力σ 2受体激动剂被开发,用6,7-二甲氧基-2- [4- [1-(4-氟苯基)-1- ħ吲哚-3- [-基]丁基] -1,2,3,4-四氢异喹啉(15)和9- [4-(6,7-二甲氧基-1,2,3,4-四氢异喹啉-2-基)丁基] -9 H -咔唑(25)示出了特殊的选择性为σ 2亚型。大多数化合物在人MCF7乳腺腺癌细胞中显示出显着的抗增殖活性,在相应的对阿霉素耐药的MCF7adr细胞系中也具有相似的活性。令人惊讶的是,其中一些化合物包括25种,显示MCF7adr细胞的活性比亲代细胞增强,回想起附带敏感性的现象,该现象正在研究中,用于治疗耐药性肿瘤。所有这些化合物均显示与P-糖蛋白(P-gp)相互作用,而15和25具有最大的活性,能够逆转P-gp介导的耐药性,并重新建立阿霉素在MCF7adr细胞中的抗肿瘤作用。因此,我们确定了一系列σ的2赋有耐人寻味抗肿瘤特性受体激动剂;